Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.

doi:10.18632/oncotarget.3343

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.

Oncotarget - 20 Mar 2015

Chen Jiayu, Xu-Monette Zijun Y, Deng Lijuan, Shen Qi, Manyam Ganiraju C, Martinez-Lopez Azahara, Zhang Li, Montes-Moreno Santiago, Visco Carlo, Tzankov Alexandar, Yin Lihui, Dybkaer Karen, Chiu April, Orazi Attilio, Zu Youli, Bhagat Govind, Richards Kristy L, Hsi Eric D, Choi William W L, van Krieken J Han, Huh Jooryung, Ponzoni Maurilio, Ferreri Andrés J M, Zhao Xiaoying, Møller Michael B, Farnen John P, Winter Jane N, Piris Miguel A, Pham Lan, Young Ken H

Abstract excerpt

Abnormal expression of the chemokine receptor CXCR4 plays an essential role in tumor cell dissemination and disease progression. However, the significance of CXCR4 overexpression in de novo diffuse large B cell lymphoma (DLBCL) is unknown. In 743 patients with de novo diffuse large B cell lymphoma (DLBCL) who received standard Rituximab-CHOP immunochemotherapy, we assessed the expression of CXCR4 and dissected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemokine CXCL12

Share to Cyclophosphamide

Share to Germinal Center

Share to Prednisone

Share to Receptors, CXCR4

Share to Rituximab

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 25704881
DOI: 10.18632/oncotarget.3343
PMCID: PMC4467389

Genes

CXCR4
BCL2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.PMID 25704881Read ↗

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read ↗

Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphomaSemantic proximity Read ↗

The CXCR4-CXCL12-Axis is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects in VitroSemantic proximity Read ↗

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.Semantic proximity Read ↗

CXC Chemokine Receptor Type 5 Gene Polymorphisms in a Cohort of Egyptian Patients with Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of Diffuse Large B-cell LymphomaSemantic proximity Read ↗

A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL.Semantic proximity Read ↗

Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomasSemantic proximity Read ↗

HGAL is a novel interleukin-4–inducible gene that strongly predicts survival in diffuse large B-cell lymphomaSemantic proximity Read ↗

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma modelsSemantic proximity Read ↗

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.Semantic proximity Read ↗

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.